Keros Therapeutics Inc. (KROS) News
Filter KROS News Items
KROS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KROS News Highlights
- KROS's 30 day story count now stands at 4.
- Over the past 24 days, the trend for KROS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about KROS are AMP, LI and UL.
Latest KROS News From Around the Web
Below are the latest news stories about KEROS THERAPEUTICS INC that investors may wish to consider to help them evaluate KROS as an investment opportunity.
Keros Therapeutics prices upsized stock offering to raise $140 millionMore on Keros Therapeutics |
HollySys Automation, Keros Therapeutics, and More Stocks See Action From Activist InvestorsActivists report to the SEC on HireRight Holdings, HollySys Automation Technologies, Rover Group, Keros Therapeutics, and Beacon Roofing Supply |
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and ExpositionKER-050 (elritercept) achieved durable transfusion independence in lower-risk MDS, including in patients with high transfusion burdenDurable clinical responses were associated with improvements in patient-reported measures of fatigueBiomarker data demonstrate that KER-050 treatment has potential to reduce NT-proBNP a measure of cardiac stressPreliminary findings from ongoing Phase 2 clinical trial in myelofibrosis demonstrate that KER-050 can not only ameliorate ineffective hematopoiesis and add |
Keros Therapeutics to Present at Upcoming Healthcare ConferencesLEXINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare |
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial ResultsLEXINGTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended September 30, 2023. “Over the |
Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and ExpositionLEXINGTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that five abstracts will be presented from its hematology program at the 65th American Society of Hematology (“ASH”) |
Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle SocietyLEXINGTON, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced results from preclinical studies evaluating the treatment effect of a research form of KER-065 (“RKER-065”) in a mou |
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial ResultsLEXINGTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended June 30, 2023. “We are excite |
Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial HypertensionLEXINGTON, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) is re-issuing this press release solely to correct inadvertent typographical errors. The corrected press release reads in its entirety as follows: Keros Therapeutics announces U.S. Food and Drug Administration (“FDA”) has cleared its investigational new drug application to conduct a Phase 2 clinical trial of KER-012 in combination with background therapy in patients with pulmonary arterial hyper |